Small Cell Lung Cancer Trials
| ClinicalTrials.gov Identifier: |
NCT05153239 |
This study is currently recruiting participants.
Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate and compare the activity and safety of two experimental arms consisting of lurbinectedin as single agent (Group A) or the combination of lurbinectedin with irinotecan (Group B) versus Investigator's Choice (topotecan or irinotecan) as control arm (Group C), in Small-cell Lung Cancer (SCLC) patients who failed one prior platinum-containing line.
Quebec
McGill University Health Centre (MUHC), Montreal
Ontario
University Health Network - Princess Margaret Hospital, Toronto
| ClinicalTrials.gov Identifier: |
NCT04155034 |
This study is currently recruiting participants.
This phase III trial studies magnetic resonance imaging (MRI) surveillance and prophylactic cranial irradiation (PCI) to see how well they work compared to MRI surveillance alone in treating patients with small cell lung cancer. MRI scans are used to monitor the possible spread of the cancer with an MRI machine over time. PCI is radiation therapy that is delivered to the brain in hopes of preventing spread of cancer into the brain. The use of brain MRI alone may reduce side effects of receiving PCI and prolong patients' lifespan. Monitoring with MRI scans alone (delaying radiation until the actual spread of the cancer) may be at least as good as the combination of PCI with MRI scans.
British Columbia
BCCA-Vancouver Island Cancer Centre, Victoria
Contact: Site Public Contact 604-877-6010
Principal Investigator: Julianna Caon
Manitoba
CancerCare Manitoba, Winnipeg
Contact: Site Public Contact 866-561-1026 [email protected]
Principal Investigator: Bashir M. Bashir
New Brunswick
Atlantic Health Sciences Corporation-Saint John Regional Hospital, Saint John
Contact: Site Public Contact 506-648-6890
Principal Investigator: Farah Naz
Newfoundland and Labrador
Doctor H. Bliss Murphy Cancer Centre, St. John's
Ontario
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton
Contact: Site Public Contact 905-387-9495
Principal Investigator: Anand Swaminath
Lakeridge Health Oshawa, Oshawa
Contact: Site Public Contact 905-576-8711 ext 4258
Principal Investigator: Joel Broomfield
Odette Cancer Centre- Sunnybrook Health Sciences Centre, Toronto
Contact: Site Public Contact 416-480-5000
Principal Investigator: Alexander V. Louie
University Health Network-Princess Margaret Hospital, Toronto
Contact: Site Public Contact 416-946-4501 [email protected]
Principal Investigator: Alexander Y. Sun
Quebec
The Research Institute of the McGill University Health Centre (MUHC), Montreal
Contact: Site Public Contact 514-934-1934 ext 48354 [email protected]
Principal Investigator: Bassam S. Abdulkarim
CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ), Quebec City
Contact: Site Public Contact [email protected]
Principal Investigator: Caroline Lavoie
Centre Hospitalier Regional de Trois-Rivieres, Trois-Rivieres
Contact: Site Public Contact 819-697-3333 ext 64399
Principal Investigator: Francois Vincent
Saskatchewan
Allan Blair Cancer Centre, Regina
Contact: Site Public Contact 306-766-2213
Principal Investigator: Nelson Leong
| ClinicalTrials.gov Identifier: |
NCT04170946 |
This study is currently recruiting participants.
This is a phase I, dose escalating study evaluating the safety of combining talazoparib and low dose consolidative thoracic radiotherapy for small cell lung cancer patients. This study will also determine the maximum tolerated dose (MTD) of talazoparib in combination with low dose thoracic radiotherapy.
Patients will start on talazoparib on day 1 of study intervention, and will continue to orally take talazoparib until the last day of radiation therapy. Up to 24 patients will be enrolled to the study, where the first 3 patients will start with a starting dose level of talazoparib is 0.5 mg PO once daily. This will increase to 1mg daily with each new cohort.
Ontario
Princess Margaret Cancer Center, Toronto
Contact: Benjamin Lok, MD 416-946-4501 ext 5819
[email protected]
| ClinicalTrials.gov Identifier: |
NCT04894591 |
This study is currently recruiting participants.
To assess the effectiveness and safety of Zepzelca in adult participants with extensive stage small cell lung cancer (SCLC) in real-world clinical practice.
New Brunswick
Horizon Health Network, The Moncton Hospital, Moncton
Nova Scotia
Cape Breton Cancer Centre, Sydney
Ontario
Southlake Regional Health Centre, Newmarket
The Ottawa Hospital Cancer Centre, Ottawa
Princess Margaret Cancer Centre, Toronto
Quebec
CIUSSS du Saguenay-Lac-Saint-Jean, Chicoutimi
Centre integre de sante et de services sociaux de Chaudiere-Appalaches Levis, Lévis
Integrated Health and Social Services Center of the Lower St. Lawrence (CISSS BSL), Rimouski
CIUSSS de l'Estrie – CHUS, Sherbrooke
Quebec Heart and Lung Institute (IUCPQ-UL), Québec
| ClinicalTrials.gov Identifier: |
NCT05060016 |
This study is active, but not recruiting participants.
The main aim of this study is to:
- evaluate safety and efficacy (per Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1] by investigator) of 2 dose levels of tarlatamab for Part 1 only
- evaluate anti-tumor activity of tarlatamab as determined by objective response rate (ORR) per RECIST 1.1 by blinded independent central review (BICR) for Part 1 and 2
- evaluate safety of reduced mandatory monitoring period in Cycle 1 at selected dose of tarlatamab for Part 3
Ontario
Princess Margaret Cancer Centre, Toronto